Chemours Co SEC Filings

Chemours Co director reports new deferred stock units. A member of the board received 1,298 deferred stock units on 12/31/2025. Each unit is the economic equivalent of one share of Chemours common stock at a reference price of $11.79. These deferred stock units, together with related dividend equivalent units, will be paid in the second calendar year after the director’s service on the board ends. Following this grant, the director beneficially owns 4,615.309 derivative securities in the form of deferred stock units, held directly.

Chemours Company director reports deferred stock units grant

A director of Chemours Company reported receiving 2,226 deferred stock units on 12/31/2025. Each deferred stock unit is the economic equivalent of one share of Chemours common stock and becomes payable in the first month after the director’s termination of service. The transaction price is listed as $11.79 per unit. Following this grant, the reporting person beneficially owns a total of 6,216.3946 deferred stock units, which include both deferred stock units and related dividend equivalent units, all held in direct ownership.

Chemours (CC) reported Q3 2025 results with net sales of $1,495 million versus $1,508 million a year ago. The company returned to profitability with net income of $60 million, or $0.40 per diluted share, compared to a net loss of $32 million in Q3 2024. Gross profit was $233 million, and selling, general and administrative expense declined to $109 million.

For the first nine months, net sales were $4,478 million and net loss was $(325) million ($(2.16) per share). Operating cash flow improved to $127 million year-to-date, versus $(771) million in the prior-year period. As of September 30, 2025, cash and cash equivalents were $613 million, with $953 million available under the revolving credit facility and current liabilities of $1,880 million. Total equity was $300 million. The company recorded a quarterly dividend of $0.0875 per share. Management revised prior periods for immaterial errors, reducing 2024 year-to-date net income by $13 million.

The Chemours Company furnished an update on its business by providing a press release and prepared remarks covering Q3 2025 financial results. The materials are included as Exhibits 99.1 and 99.2 and are designated as “furnished,” not “filed,” under the Exchange Act.

The company plans to post an investor presentation and the prepared remarks to its investor relations website by 8:00 a.m. Eastern Daylight Time on Friday, November 7, 2025, aligned with its scheduled conference call.

The Chemours Company adopted an Executive Severance Policy effective October 28, 2025. The policy covers executive officers and designated employees who are involuntarily terminated without Cause or resign for Good Reason. Eligible participants receive accrued and unpaid base salary, bonus or incentive compensation, and vacation pay. The CEO is eligible for a cash severance equal to 2.0 times the sum of base salary, target annual incentive opportunity, and annualized health care subsidy; other executive officers and employees receive 1.0 times that sum. A prorated annual cash incentive is payable based on actual performance for the portion of the year worked.

The policy requires a signed release of claims to receive benefits. It does not supersede any change in control agreements and does not alter the treatment of outstanding equity awards, which remain governed by existing plans and award agreements.

The Chemours Company amended its credit agreement, extending the maturity of its $1,050,000,000 senior secured U.S. dollar term loan (Term Loan B-3) from August 18, 2028 to October 15, 2032. The loan’s pricing was reset to either adjusted Term SOFR + 3.50% or adjusted base rate + 2.50%, at the company’s election.

Separately, several wholly owned European subsidiaries entered a receivables purchase agreement with BNP Paribas Factor allowing sales of eligible receivables up to an aggregate outstanding balance of €180,000,000. The initial term runs through October 14, 2026 with automatic one-year extensions, and Chemours acceded to joint and several liability for seller obligations. Receivables are sold at their nominal amount less customary deductions, with applicable interest and fees payable to BNP.

Chemours director Satterthwaite Livingston received 966 deferred stock units on 09/30/2025, each equal to one share of Chemours common stock and recorded at an acquisition price of $15.84 per unit. After the transaction the reporting person beneficially owns 3,280.0507 shares (direct). The deferred stock units become payable beginning the second calendar year after the reporting person ceases service as a director, so these units represent compensation that vests for payout on termination rather than immediate cash or share delivery. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and identifies the reporting person as a director of Chemours (ticker: CC).

Courtney Mather, a director of Chemours Co (CC), reported acquisition of deferred stock units tied to common shares on 09/30/2025. The Form 4 shows 1,657 deferred stock units were acquired at a reported unit value of $15.84 each. Each deferred stock unit is the economic equivalent of one share of common stock and becomes payable after the director leaves board service. After the reported transaction the filing indicates the reporting person beneficially owns 3,960.9731 shares in a direct ownership form.

Gerardo Familiar Calderon, an officer at The Chemours Company (CC), reported a transaction dated 09/01/2025 in which 1,294 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the withholding was executed at a price of $15.40 per share and no shares were sold. The filing shows 33,949.9429 shares beneficially owned following the transaction; that total was reduced to correct an inadvertent over-reporting in a prior Form 4 filed August 5, 2025. The Form 4 was executed on 09/03/2025 by an attorney-in-fact.